CA2294568A1 - Vaccins contre la maladie de lyme - Google Patents

Vaccins contre la maladie de lyme Download PDF

Info

Publication number
CA2294568A1
CA2294568A1 CA002294568A CA2294568A CA2294568A1 CA 2294568 A1 CA2294568 A1 CA 2294568A1 CA 002294568 A CA002294568 A CA 002294568A CA 2294568 A CA2294568 A CA 2294568A CA 2294568 A1 CA2294568 A1 CA 2294568A1
Authority
CA
Canada
Prior art keywords
polypeptide
burgdorferi
polypeptides
amino acid
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002294568A
Other languages
English (en)
Inventor
Gil H. Choi
Alice L. Erwin
Mark S. Hanson
Raju Lathigra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
MedImmune LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2294568A1 publication Critical patent/CA2294568A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Cette invention se rapporte à de nouveaux vaccins permettant de prévenir ou d'atténuer la maladie de Lyme. Cette invention se rapporte en outre à des molécules d'acides nucléiques isolées codant des polypeptides antigéniques de Borrelia burgdorferi. Cette invention présente également des polypeptides antigéniques, ainsi que des vecteurs, de cellules hôtes et des procédés de recombinaison pour la production de ceux-ci. Cette invention se rapporte en outre à des procédés de diagnostic pour détecter l'expression de gènes de Borrelia.
CA002294568A 1997-06-20 1998-06-18 Vaccins contre la maladie de lyme Abandoned CA2294568A1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US5035997P 1997-06-20 1997-06-20
US60/050,359 1997-06-20
US5337797P 1997-07-22 1997-07-22
US5334497P 1997-07-22 1997-07-22
US60/053,344 1997-07-22
US60/053,377 1997-07-22
US5748397P 1997-09-03 1997-09-03
US60/057,483 1997-09-03
PCT/US1998/012718 WO1998059071A1 (fr) 1997-06-20 1998-06-18 Vaccins contre la maladie de lyme

Publications (1)

Publication Number Publication Date
CA2294568A1 true CA2294568A1 (fr) 1998-12-30

Family

ID=27489331

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002294568A Abandoned CA2294568A1 (fr) 1997-06-20 1998-06-18 Vaccins contre la maladie de lyme
CA002304925A Abandoned CA2304925A1 (fr) 1997-06-20 1998-06-18 Polyucleotides de borrelia burgdorferi et sequences correspondantes

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002304925A Abandoned CA2304925A1 (fr) 1997-06-20 1998-06-18 Polyucleotides de borrelia burgdorferi et sequences correspondantes

Country Status (4)

Country Link
EP (2) EP1012157A1 (fr)
AU (2) AU8153498A (fr)
CA (2) CA2294568A1 (fr)
WO (2) WO1998059071A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2303409A1 (fr) * 1997-09-10 1999-03-18 Yale University Synthetase d'arnt de lysyle de classe-i
GB9808423D0 (en) * 1998-04-22 1998-06-17 Glaxo Group Ltd Bacterial polypeptide family
EP1117783B1 (fr) * 1998-09-30 2010-02-17 Agensys, Inc. Gene exprime dans le cancer de la prostate
FR2798386B1 (fr) * 1999-09-10 2003-04-25 Didier Raoult Oligonucleotides monocatenaires, sondes, amorces et procede de detection des spirochetes
WO2002006491A1 (fr) * 2000-07-18 2002-01-24 Center For Advanced Science And Technology Incubation, Ltd. Isopentenyl pyrophosphate isomerase
CA2418087A1 (fr) * 2000-08-16 2002-02-21 Markus Fritzsche Utilisation de sequences d'adn microbiennes pouvant identifier des maladies humaines
CN1223602C (zh) 2001-07-13 2005-10-19 一泰医药研究（深圳）有限公司 序列号11的生物活性肽
WO2004005479A2 (fr) * 2002-07-02 2004-01-15 Arizona Board Of Regents Systeme de typage haute resolution pour borrelia pathogene
CN103589650A (zh) 2005-03-18 2014-02-19 米克罗比亚公司 产油酵母和真菌中类胡萝卜素的产生
JP2010503384A (ja) * 2006-09-15 2010-02-04 インターセル アーゲー ボレリア（Ｂｏｒｒｅｌｉａ）抗原
WO2008042338A2 (fr) 2006-09-28 2008-04-10 Microbia, Inc. Production de caroténoïdes dans des levures et des champignons oléagineux
US9297803B2 (en) * 2006-11-01 2016-03-29 Immport Therapeutics, Inc. Compositions and methods for immunodominant antigens
EP2191266A4 (fr) * 2007-09-07 2011-08-03 Univ California Procédés de diagnostic et de criblage concernant borrelia
RU2580299C2 (ru) 2009-06-29 2016-04-10 Дженосеа Биосайенсиз, Инк. Вакцины и композиции, направленные против streptococcus pneumoniae
WO2012100233A1 (fr) 2011-01-20 2012-07-26 Genocea Biosciences, Inc. Vaccins et compositions contre streptococcus pneumoniae
CA2863661C (fr) 2012-02-01 2021-06-01 Biopeptides Corp Peptides diagnostiques pour la maladie de lyme
FR3009683A1 (fr) * 2013-08-14 2015-02-20 Univ Strasbourg Vaccins contre la maladie de lyme
WO2016049148A1 (fr) 2014-09-24 2016-03-31 Wellstat Diagnostics, Llc Compositions et méthodes de diagnostic de la maladie de lyme
EP3135295A1 (fr) * 2015-08-28 2017-03-01 Latvian Biomedical Research and Study Centre Couplage de protéines de borrelia bb0689 à particules pseudo-virales pour génération de vaccin contre la maladie de lyme
US11739388B2 (en) 2016-11-03 2023-08-29 University Of Leicester Phage-based detection of borreliosis and means therefor
EP3643796A1 (fr) * 2018-10-25 2020-04-29 TBD-diagnostics GmbH Diagnostic de la maladie de lyme
CA3175297A1 (fr) 2020-04-13 2021-10-21 Jyotsna Shah Detection de la maladie de lyme
CA3266500A1 (fr) * 2022-09-02 2024-03-07 The Medical College Of Wisconsin, Inc. Utilisation d'épitopes de lymphocytes t immunogènes pour la vaccination et le diagnostic de la maladie de lyme

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
CA2025178A1 (fr) * 1989-10-02 1991-04-03 William G. Weisburg Sondes d'acide nucleique pour la detection des spirochetes de la maladie de lyme

Also Published As

Publication number Publication date
AU8151898A (en) 1999-01-04
CA2304925A1 (fr) 1998-12-30
WO1998059071A1 (fr) 1998-12-30
WO1998058943A1 (fr) 1998-12-30
EP1009859A1 (fr) 2000-06-21
AU8153498A (en) 1999-01-04
EP1012157A1 (fr) 2000-06-28

Similar Documents

Publication Publication Date Title
US6913907B2 (en) Enterococcus faecalis polynucleotides encoding EF059
DK0942983T4 (en) Streptococcus pneumoniae antigens and vaccines
CA2294568A1 (fr) Vaccins contre la maladie de lyme
US6607728B2 (en) Compounds and methods for the diagnosis and treatment of ehrlichia infection
WO1998042740A9 (fr) COMPOSES ET PROCEDES DE DIAGNOSTIC ET DE TRAITEMENT DE L'INFECTION PAR $i(EHRLICHIA)
US6277381B1 (en) Compounds and methods for the diagnosis and treatment of Ehrlichia infection
US6821754B2 (en) Staphylococcus aureus genes and polypeptides
US6902893B1 (en) Lyme disease vaccines
WO2000012678A2 (fr) Genes de staphylococcus aureus et polypeptides associes
US20020086984A1 (en) Compounds and methods for the diagnosis and treatment of Ehrlichia infection
US20020068343A1 (en) Compounds and methods for the diagnosis and treatment of ehrlichia infection
US6887663B1 (en) Streptococcus pneumoniae SP036 polynucleotides
CA2296814A1 (fr) Polynucleotides et sequences de treponema pallidium
US6673356B1 (en) Compounds and methods for the diagnosis and treatment of ehrlichia infection
WO1999002700A1 (fr) Gene regulateur a deux composantes - dont l'histidine kinase - issu du candida albicans
AU8938601A (en) Lyme disease polynucleotides

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued